IL182652A0
(en )
2007-07-24
Nitrobenzindoles and their use in cancer therapy
EP1835929B8
(en )
2016-07-27
Anti-kir combination treatments and methods
GB0418328D0
(en )
2004-09-22
Cancer methods and medicaments
AU2003235470A1
(en )
2004-01-06
Predictive markers in cancer therapy
AU2003209594A1
(en )
2003-09-22
Quinazoline compounds useful in therapy
EP1749095A4
(en )
2007-12-19
Novel therapeutic targets in cancer
IL178012A0
(en )
2006-12-31
Diphenyl-indol-2-on compounds and their use in the treatment of cancer
IL181608A0
(en )
2007-07-04
Cancer combination therapy comprising azd2171 and imatinib
EP1838288A4
(en )
2010-08-04
Therapeutic materials and methods
GB0428170D0
(en )
2005-01-26
Mono and Combination Therapy
GB0426903D0
(en )
2005-01-12
Complexes and methods
GB0407382D0
(en )
2004-05-05
Therapeutic methods and means
GB0700827D0
(en )
2007-02-21
Hai-1 and Hai-2 in cancer therapy
AU2003283339A1
(en )
2004-06-07
Cancer therapy determination
HK1103350A
(en )
2007-12-21
Hai-1 and hai-2 in cancer therapy
AU2003291896A1
(en )
2004-07-14
Saponins and sapogenins for use in combination therapy for cancer
GB2448627B
(en )
2010-07-14
Combination therapy and antibody panels
HK1106699A
(en )
2008-03-20
Cancer combination therapy comprising azd2171 and imatinib
ZA200702220B
(en )
2008-09-25
Cancer combination therapy comprising AZD2171 and imatinib
GB0421914D0
(en )
2004-11-03
Drug metabolising enzyme in cancer
HK1087104A
(en )
2006-10-06
Quinoline derivates and their use in therapy
AU2004901544A0
(en )
2004-04-08
Cancer and testis proteins and uses thereof
HK1095858A
(en )
2007-05-18
Methods and materials for assessing prostate cancer therapies
HK1106428A
(en )
2008-03-14
Cancer treatments
GB0424871D0
(en )
2004-12-15
Antibodies and their use in therapy